KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Charles River Laboratories International (CRL) Debt to Equity (2016 - 2025)

Charles River Laboratories International has reported Debt to Equity over the past 17 years, most recently at $0.67 for Q4 2025.

  • Quarterly results put Debt to Equity at $0.67 for Q4 2025, up 4.14% from a year ago — trailing twelve months through Dec 2025 was $0.67 (up 4.14% YoY), and the annual figure for FY2025 was $0.67, up 4.14%.
  • Debt to Equity for Q4 2025 was $0.67 at Charles River Laboratories International, up from $0.64 in the prior quarter.
  • Over the last five years, Debt to Equity for CRL hit a ceiling of $1.19 in Q3 2021 and a floor of $0.61 in Q3 2024.
  • Median Debt to Equity over the past 5 years was $0.8 (2025), compared with a mean of $0.86.
  • Biggest five-year swings in Debt to Equity: increased 12.36% in 2021 and later crashed 31.98% in 2023.
  • Charles River Laboratories International's Debt to Equity stood at $1.05 in 2021, then fell by 13.51% to $0.91 in 2022, then fell by 19.09% to $0.73 in 2023, then decreased by 11.93% to $0.65 in 2024, then increased by 4.14% to $0.67 in 2025.
  • The last three reported values for Debt to Equity were $0.67 (Q4 2025), $0.64 (Q3 2025), and $0.69 (Q2 2025) per Business Quant data.